权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents

开发病原体识别受体激动剂作为潜伏期逆转剂

基本信息

批准号：
9501675
负责人：
Alberto Bosque
金额：
$ 49.61万
依托单位：
GEORGE WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9501675
关键词：
Adjuvant Agonist Anti-Retroviral Agents Antiviral Agents Asthma Autoimmunity Bacterial Infections Bromodomain CD4 Positive T Lymphocytes Cell model Cells Clinical Clinical Trials Communicable Diseases Consequentialism Data Disease Disease remission Epigenetic Process Evaluation Gene Expression Genetic Transcription Goals Guanosine Triphosphate Phosphohydrolases HIV HIV-1 HIV-1 protease Histone Acetylation Histone Deacetylase Histone Deacetylase Inhibitor In Vitro Infection Interferons Interphase Cell Investigation Latent Virus Lead Ligands MGMT gene Maintenance Mitochondria Mitochondrial Proteins Modeling Nucleic Acids Pathway interactions Patients Pharmaceutical Preparations Pharmacology Protein Kinase C Proteins Role SIRT1 gene Shock Signal Transduction Signaling Protein T-Cell Activation Technology Therapeutic Thinking Tumor Cell Line Vaccination Viral Viral Genes Viral reservoir Virus Diseases Virus Latency base bryostatin cancer therapy design immune activation inhibitor/antagonist latent infection novel novel strategies novel therapeutic intervention pathogen reactivation from latency receptor response screening synergism therapeutic target

项目摘要

The existence of latent reservoirs of HIV-infected cells constitutes the major impediment towards viral eradication. HIV-1 latent reservoirs are small, but extremely long-lived. Latent infection is associated with undetectable levels of viral gene expression and appears to be non-cytopathic. However, upon reactivation, latent viruses enter an active mode of replication in which they are fully competent for spread and induction of disease. The current thinking in the field is that a combination of hypothetical drugs that will reactivate latent viruses (Latency Reversing Agent or LRA), with present-day antiretroviral drugs, will be an effective approach toward viral eradication. We have previously found that Pam3CSK4, a TLR-1/2 agonist, can reactivate latent HIV-1. Based on this earlier finding, we propose to further investigate the possibility of developing Pathogen Recognition Receptor (PRR) agonists as novel strategies to reactivate/eradicate latent HIV-1 infection. In Aim 1, we plan to characterize the ability of multi-PRR agonists to reactivate latent HIV-1. Multi-PRR agonists are synthetic TLR agonists developed by InvivoGen to be used as adjuvants in cancer therapy, infectious diseases and vaccination. Our preliminary data using the tumoral cell line JLat, a primary model of HIV-1 latency (Cultured TCM model) and cells isolated from aviremic patients demonstrate that these ligands have the ability to reactivate latent HIV-1. Furthermore, in this aim we also plan to evaluate the potential of this agonist to reduce the latent reservoir in vitro. We have found that dynasore, a GTPase inhibitor, has the ability to reactivate latent HIV-1. It has been proposed that dynasore activates the PRR mitochondria antiviral signal protein (MAVS). We have further corroborated this result. Based on this notion, this aim is designed to characterize whether manipulation of the RIG-I/MDA-5/MAVS pathway can have therapeutic implications towards HIV-1 eradication. First, we are going to study whether RIG-1 and MDA-5 ligands that signal through MAVS can reactivate latent HIV-1. Second, it has been shown that the HIV-1 protease can induce lysosomal degradation of RIG-I to avoid sensing and the induction of an interferon response. We plan to characterize whether this mechanism is involved in the establishment of latency. Lastly, identifying novel mechanisms that are involved in the maintenance of latency would lead to the design of novel therapeutic approaches. We have performed a screening to identify epigenetic modulators that synergize with the synthetic TLR-2 ligand CL572. We have identified several pathways that synergize with CL572. In Aim 3, we plan to characterize in detail the mechanism of synergy between PRR agonists and two known pathways, HDACs and bromodomain proteins, and two novel pathways, O6-Methylguanine-DNA methyltransferase and sirtuin-1 and -2. The overall goal of this proposal is to move forward novel targets that can be exploited therapeutically to either eradicate viral reservoirs for HIV-1 infections or to induce a long-term remission without treatment (functional cure).

hiv感染细胞的潜伏储存库的存在构成了病毒的主要障碍